

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	Fi	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/980,916	02/19/2002		Steen Klysner	3631-0112P	3837	
2292	7590	08/30/2006		EXAMINER		
BIRCH ST PO BOX 74		KOLASCH & BIF	HISSONG, BRUCE D			
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER		
			1646			

DATE MAILED: 08/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
09/980,916	KLYSNER, STEEN		
Examiner	Art Unit		
Bruce D. Hissong, Ph.D.	1646		

	Bruce D. Hissong, Ph.D.	1646	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	ress
 THE REPLY FILED <u>17 March 2006</u> FAILS TO PLACE THIS AF		·	
The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follor places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in complian- time periods:	the same day as filing a Notice of wing replies: (1) an amendment, aft otice of Appeal (with appeal fee) in o	Appeal. To avoid aba fidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) \boxtimes The period for reply expires <u>6</u> months from the mailing date	e of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Examiner Note: If box 1 is checked, check either box (a) or	ater than SIX MONTHS from the mailin (b). ONLY CHECK BOX (b) WHEN THI	g date of the final rejecti	on.
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7 Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exampler 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	on which the petition under 37 CFR 1. dension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) as
2. The Notice of Appeal was filed on 17 March 2006. A brief the date of filing the Notice of Appeal (37 CFR 41.37(a)), appeal. Since a Notice of Appeal has been filed, any replacements.	or any extension thereof (37 CFR	41.37(e)), to avoid dis	missal of the
AMENDMENTS	•		• •
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below)	nsideration and/or search (see NO		ecause
(c) They are not deemed to place the application in be appeal; and/or			the issues for
(d) They present additional claims without canceling a		ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)). The amendments are not in compliance with 37 CFR 1.1		mpliant Amandment	(DTOL 324)
5. Applicant's reply has overcome the following rejection(s)		mphant Amendment	(PTOL-324).
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 		timely filed amendme	ent canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ill be entered and an e	explanation of
Claim(s) objected to: Claim(s) rejected: 77-80, 85-87, 89-94, 100, 133. Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
3. The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).			
O. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe y and was not earlier presented. S	al and/or appellant fa See 37 CFR 41.33(d)(ils to provide a 1).
10. The affidavit or other evidence is entered. An explanation of the control		·	
 The request for reconsideration has been considered by 	ut does NOT place the application i	n condition for allowa	nce because:
 12. ☐ Note the attached Information Disclosure Statement(s). 13. ☐ Other: See Continuation Sheet. 	(PTO/SB/08 or PTO-1449) Paper N	No(s)	

Continuation of 13. Other: In response to the Applicant's arguments, amendments to the claims, and/or cancellation of claims 73-75, all rejections under 35 U.S.C. 112, first paragraph are withdrawn, except for the following:

- 1. Claims 92-94 remain rejected under 35 U.S.C. 112, first paragraph, regarding lack of written description, and lack of enablement, for IL-5 polypeptide "analogs", for reasons of record set forth in the previous office actions.
- 2. Claims 77-80, 85-87, 89-94, 100, and 133 remain rejected under 35 U.S.C. 112, first paragraph, regarding lack of written description, and lack of enablement, for IL-5 polypeptides with unlimited modifications, for reasons of record set forth in the previous office actions. Briefly, although claim 85 limits modifications to insertion/replacement of specific loops or regions of the IL-5 polypeptide, independent claims 100 and 133 are drawn to an IL-5 polypeptide wherein at least one foreign epitope is introduced into the sequence of the IL-5 polypeptide, and as written, encompasses introduction of a foreign epitope into any region of the IL-5 polypeptide. Claims 77-80, 85-87, and 89-94 are rejected for depending from claim 133.

Additionally, claims 92-94 are rejected under 35 U.S.C. 112, second paragraph. Due to the amendments to claim 91 to remove the term "analog" from the claim, the term "the IL-5 analog", as recited in claims 92-94, lacks antecedent basis. This rejection is necessitated by amendment to claim 91.

All rejections under 35 U.S.C. 103 are withdrawn in response to Applicant's arguments. Briefly, there is no motivation to modify the exact regions of the IL-5 polypeptide as recited in claim 85 in order to practice the instant invention. Regarding rejection of independent claims 100 and 133, the rejection under 35 U.S.C. 103 is being withdrawn in light of the rejection under 35 U.S.C. 112, first paragraph, as set forth above.

ROBERT S. LANDSMAN, PH PRIMARY EXAMINER